knowledge -WSS

knowledge

author：focus 2025-09-29 17:02:13 - browse：945

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Covid vaccines: Private market messier than government rollout

hotspot

WSS

European regulators recommend Amylyx's ALS drug be rejected

WHO recommends dropping component of many flu vaccines

FDA seeks to regulate lab

Female surgeons have lower rates of long

Health tech startups drop sharply from 2021 highs

FDA seeks to regulate lab

Wikipedia

knowledge

explore

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: Merger Mondays, Ozempic panic

Jerome Adams on the need for new antivirals for Covid

Senator probes 340B programs at Cleveland Clinic, Bon Secours

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Hollywood unions extend contract negotiations for actors

What the Wegovy shortage looks like for doctors — and for patients

Medical records are filled with copy

Researchers use wearables data and AI to predict preterm birth risk

hotspot

Paxlovid should be available without a positive Covid test

Menendez indictment could see pharma lose a key ally

Humana CEO Bruce Broussard to step down in 2024

Intercept Pharmaceuticals sells itself for less than $1 billion

Eight reasons why you should get an updated Covid vaccine

Wellcome Trust names Røttingen as its new CEO

hotspot

leisure time

hotspot

Wikipedia